09:12 EST Sana jumps 275% to $6.20 with diabetes data viewed as ‘best case’
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA:
- H.C. Wainwright ups Sana target after ‘best case scenario’ data
- Sana Biotechnology (NASDAQ:SANA) Soars 400% on Breakthrough Diabetes Transplant
- Sana Biotechnology upgraded to Buy from Hold at TD Cowen
- Closing Bell Movers: Cal-Maine Foods up 5% on Q2 results
- Sana Biotechnology up 285% afterhours following type 1 diabetes study data